AEON Biopharma, Inc. Form 8-K Summary
Business Context and Reporting Period
AEON Biopharma, Inc., an emerging growth company incorporated in Delaware, filed this Current Report on Form 8-K on December 18, 2024. The Company is headquartered in Irvine, California, and its Class A Common Stock trades on the NYSE American under the symbol "AEON."
Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document is a current report regarding corporate governance changes rather than a periodic financial report.
Material Changes
On December 18, 2024, the Company amended its amended and restated bylaws to modify the quorum requirement for shareholder meetings. The quorum threshold was reduced from a majority of the voting power of outstanding shares to 33.34% of the voting power of outstanding shares entitled to vote at a meeting.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The sole purpose of the report is to disclose the amendment to the Bylaws.
Key Facts for Investor Verification
- The quorum requirement for shareholder meetings has been lowered to 33.34% of voting power.
- The amendment was effective as of December 18, 2024.
- The Certificate of Amendment to Bylaws is filed as Exhibit 3.1.
- No financial performance data is provided in this specific filing.